To ascertain whether osteoblast or megakaryocyte/platelet-derived SCF played a role in prostate cancer progression, we depleted SCF in osteoblasts via the osteocalcin promoter and in megakaryocytes/platelets via the platelet factor 4 promoter using a conditional knockout murine model. This evidence concerns the gene KITLG and prostate carcinoma.